Holocene Advisors LP Purchases New Holdings in InMode Ltd. (NASDAQ:INMD)

Holocene Advisors LP purchased a new position in InMode Ltd. (NASDAQ:INMD - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 50,320 shares of the healthcare company's stock, valued at approximately $853,000. Holocene Advisors LP owned about 0.06% of InMode at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of INMD. Vanguard Group Inc. increased its position in InMode by 0.6% during the first quarter. Vanguard Group Inc. now owns 751,537 shares of the healthcare company's stock worth $16,241,000 after buying an additional 4,387 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in InMode by 24.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 59,610 shares of the healthcare company's stock worth $1,289,000 after buying an additional 11,643 shares during the last quarter. California State Teachers Retirement System increased its position in InMode by 2.9% during the first quarter. California State Teachers Retirement System now owns 94,516 shares of the healthcare company's stock worth $2,042,000 after buying an additional 2,696 shares during the last quarter. Cetera Advisors LLC increased its position in InMode by 8.9% during the first quarter. Cetera Advisors LLC now owns 17,028 shares of the healthcare company's stock worth $368,000 after buying an additional 1,394 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in InMode during the second quarter worth $417,000. 68.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research report on Thursday, October 31st. Barclays lowered their price target on InMode from $29.00 to $27.00 and set an "overweight" rating on the stock in a research report on Monday, October 14th. Finally, BTIG Research assumed coverage on InMode in a research report on Thursday, October 17th. They issued a "buy" rating and a $25.00 price target on the stock. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, InMode has an average rating of "Hold" and a consensus price target of $22.60.

InMode Stock Up 0.1 %

INMD traded up $0.02 during midday trading on Friday, reaching $18.13. 548,555 shares of the company's stock were exchanged, compared to its average volume of 1,032,537. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of 9.80 and a beta of 2.07. InMode Ltd. has a one year low of $14.87 and a one year high of $26.80. The business has a 50-day simple moving average of $17.81 and a two-hundred day simple moving average of $17.49.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.